Age-multiplied low density lipoprotein cholesterol (LDL-C) burden (AM-LDL) index stratifies bleeding and ischemic risk in acute coronary syndrome: implications for early therapeutic intensification Authors: Yani Yu, Ying Wang, Xiaodan Tuo, Zongxing Li, Dandan Li, Yundai Chen Published: 2025 ABSTRACT BackgroundEarly identification of high-risk individuals after Acute Coronary Syndrome (ACS) is critical for tailoring intensive lipid-lowering therapy, a cornerstone of secondary prevention to alleviate the growing global burden of cardiovascular diseases, while practical tools integrating lipid burden and vascular aging remain lacking. This study proposes the age-multiplied low density lipoprotein cholesterol (LDL-C) burden (AM-LDL) index to quantify cumulative atherogenic exposure and stratify 1-year ischemic and bleeding risk.MethodsThis post-hoc analysis utilized data from the prospective “Beijing Risk Intervention Clinical (BRIC) Study”, which enrolled post-percutaneous coronary intervention (PCI) ACS patients from a 30-center Chinese cohort and followed them for one year. AM-LDL was calculated by multiplying the admission LDL-C concentration by the patient’s age. Study endpoints comprised Bleeding Academic Research Consortium (BARC) type ≥ 2 bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE).ResultsAmong the 5658 participants, 309 experienced BARC ≥ 2 bleeding event, 156 had MACE, and 454 developed NACE. AM-LDL showed a significant association with MACE and NACE in Kaplan-Meier analysis (log-rank P = 0.002 for each), in contrast to bleeding (P = 0.055). Subsequent multivariable Cox modeling sustained its independent association with MACE (Hazard Ratio [HR] = 2.623, 95% Confidence Interval [95%CI]: 1.411–4.876, P = 0.002) and NACE (HR = 1.520, 95% CI: 1.094–2.111, P = 0.012), but not with bleeding (HR = 1.203, 95% CI: 0.815–1.775, P = 0.353). Restricted cubic spline analysis revealed a linear dose-response relationship, and an inverted U-shaped association with NACE, while no nonlinear correlation was detected for bleeding.ConclusionThe AM-LDL index, derived from two readily available admission parameters, is associated with post-discharge one-year MACE and NACE risks among ACS patients. Its application may help improve risk stratification, allowing for timely treatment intensification and a more personalized prevention strategy, while warranting validation in interventional trials before clinical implementation.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12944-025-02789-y. Introduction The timely detection of high-risk patients is crucial in acute coronary syndrome (ACS) to guide aggressive secondary preventive management. While current guidelines emphasize aggressive lipid-lowering, a critical gap persists: the lack of simple bedside tools integrating cumulative lipid burden and vascular aging to guide therapy escalation at discharge [1]. However, atherosclerosis progression is a chronic process, necessitating consideration of the temporal impact of low density lipoprotein cholesterol (LDL-C) on endothelial injury. Studies have shown that aging exponentially accelerates LDL-induced endothelial dysfunction through mechanisms like reduced cholesterol efflux capacity and nitric oxide bioavailability [2, 3]. And also, the atherogenic impact of LDL-C depends not only on current levels but also on the vascular microenvironment shaped by decades of lipid exposure [4], implying that equivalent atherogenic potential may arise from either high LDL-C in youth or moderate LDL-C in advanced age. Conventional risk models fail to capture this synergy, as they rely on static LDL-C measurements while neglecting the temporal dimension of lipid exposure. Recent advances in vascular biology propose that the product of LDL-C and age (LDL × Age) may serve as a surrogate for “atherogenic momentum”—the rate at which lipid accumulation outpaces vascular repair capacity [5, 6]. This concept is mechanistically grounded in large-scale proteomic studies showing age-dependent upregulation of LDL retention proteoglycans in arterial walls [7, 8], and clinically validated by the NATURE-PARADOX trial demonstrating LDL × Age’s superiority over isolated LDL measurements in predicting plaque progression [9]. However, beyond its established link with ischemic risk, emerging evidence suggests that very low LDL-C levels have been linked to an elevated risk of bleeding, possibly related to altered platelet function or coagulation pathways [10]. As the age-multiplied LDL-C burden (AM-LDL) index reflects residual atherogenic lipid risk, its relationship with bleeding outcomes remains unexplored. The management of atherosclerotic cardiovascular disease requires a careful balancing act between preventing ischemia and mitigating bleeding risk, especially for patients receiving percutaneous coronary intervention (PCI)- there is currently no integrated lipid-based biomarker capable of simultaneously stratifying both ischemic and bleeding risks. Accordingly, this study evaluated the AM-LDL index, a simple metric calculated from two routine admission variables, for stratifying post-PCI ACS patients according to their one-year risks of both bleeding and ischemic events, and clarifying which individuals are most likely to benefit to benefit—with agents such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors—from early intensive lipid-lowering therapy (LLT), thus supporting better risk-benefit optimization at discharge. Method Study population Patients were enrolled from the “Beijing Risk Intervention Clinical (BRIC) Study”, a nationwide, multicenter, prospective, non-interventional registry. Designed to assess bleeding risk, the BRIC Study consecutively enrolled ACS patients who received dual antiplatelet therapy (DAPT) after PCI at 30 Chinese centers. Participants were prospectively followed for one year during two enrollment periods: May 2014-January 2016 and October 2017-April 2019. Eligibility required: (1) Aged 18 years or above; (2) A confirmed diagnosis of ACS, encompassing all subtypes—ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA); (3) Received PCI treatment; (4) Agreed to one-year follow-up; and (5) Provided written informed consent. Exclusion criteria: (1) Secondary ACS etiologies attributable to trauma-induced vascular injury, hemorrhagic/peri-procedural supply-demand mismatch, or iatrogenic coronary complications—all verified through angiographic absence of vulnerable plaque, hemodynamic biomarkers [1, 11]; (2) Pregnant or lactating women; (3) Patients deemed unsuitable for the study by the investigators; (4) Missing baseline lipid information and grossly abnormal data quality. The study flow is depicted in Fig. 1, with a final sample of 5658 participants. Ethical approval for this study was granted by the Institutional Review Board of Chinese PLA General Hospital (No. S2017-098). All enrolled participants provided written informed consent, and the study adhered to the principles of the Declaration of Helsinki. The BRIC study was registered at clinicaltrials.org as NCT03402711. Fig. 1Study flow chart Study flow chart Data collection The study systematically collected baseline clinical information from eligible patients, encompassing demographic data (e.g., gender, age, smoking, drinking history), medical history (e.g., coronary artery disease [CAD, defined as prior clinician-diagnosed CAD before index hospitalization, evidenced by PCI, coronary artery bypass grafting [CABG], thrombolytic therapy, et al., while patients with first-time CAD diagnosis during index ACS event were classified as ‘no prior CAD’], prior PCI, heart failure, diabetes, hypertension, hyperlipidemia, chronic kidney disease, stroke, gastrointestinal bleeding, peripheral vascular disease, atrial fibrillation), current illness history (e.g., diagnosis, heart function classification), anthropometric measurements (e.g., weight, height), vital signs (e.g., heart rate, blood pressure, pulse) and laboratory tests (e.g., lipid profiles, complete blood count, infection markers, biochemical assessments). Intra-hospital treatment data were also documented, detailing the interventional procedure (e.g., lesion characteristics, primary PCI, thrombus aspiration, stent deployment count), postoperative medications (e.g., glycoprotein IIb/IIIa [GPIIb/IIIa] receptor antagonists, low molecular weight heparin, bivalirudin), discharge antiplatelet therapy (e.g., aspirin, clopidogrel, ticagrelor), and concomitant medication regimens (e.g., statins, renin-angiotensin-aldosterone system antagonists, beta-blockers, proton pump inhibitors, calcium channel blockers). Follow-up and endpoint Longitudinal assessments were performed throughout the 12-month study, with visits scheduled at discharge and 1-, 3-, 6-, and 12 months thereafter. Follow-up modalities included telephone interviews and clinical visits. At the 1- and 6-month timepoints, evaluations were permitted via telephone or in-person visits. For the 3- and 12-month assessments, in-person visits were strongly encouraged. All visits encompassed laboratory parameter reassessment, medication regimen adjustments and documentation of clinical outcome events. An independent clinician, blinded to all patient data, adjudicated all clinical endpoint events. The primary outcomes of this study consisted of bleeding events, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Based on the Bleeding Academic Research Consortium (BARC) criteria [12], clinically relevant bleeding was classified as BARC type 2, type 3 and type 5. MACE was operationalized as a composite of death from any cause, non-fatal myocardial infarction, non-fatal ischemic stroke, or the need for urgent coronary revascularization. NACE was characterized as the composite of clinically relevant bleeding events and any component of MACE. Upon obtaining written informed consent, the follow-up period commenced. Survival time was calculated from enrollment until the first event or last follow-up, whichever occurred first, within the 12-month study period. DAPT adherence was evaluated via prospective telephone interviews at 1, 6, and 12 months after discharge, supplemented by electronic health record reviews. Continuous DAPT was defined as no recorded discontinuation of aspirin or P2Y12 receptor inhibitors (including clopidogrel and ticagrelor) for > 7 consecutive days during the 12-month period. Statistical analysis The analysis utilized descriptive statistical methods. Normally distributed continuous data are reported as mean ± standard deviation, and non-normally distributed data as median (interquartile range). Categorical variables are presented as number (percentage). Appropriate inferential tests (Student’s t-test, Mann-Whitney U test, chi-square test, or Fisher’s exact test) were selected based on the data distribution and scale. The AM-LDL index was calculated as baseline LDL-C (mmol/L) multiplied by age (years), which was stratified into quartiles for analysis with the lowest quartile designated as the referent group. Trend analyses for ordinal categorical outcomes were performed using the Mantel-Haenszel test for linear association. The associations of AM-LDL with outcomes were assessed with the application of Kaplan-Meier analysis, along with univariate and multivariate Cox regression. Additionally, restricted cubic spline (RCS) regression was employed to examine potential nonlinear relationships. Multivariable Cox proportional hazards regression models were employed with covariate selection guided by three principles endorsed by international guidelines: clinical necessity, mixed control, and event driven constraints. The construction of hierarchical models proceeded as follows: Model 1 included adjustments for sociodemographic and lifestyle characteristics, namely gender, body mass index (BMI), smoking status, and drinking; while Model 2 expanded to clinical covariates, including the history of CAD, hypertension, diabetes, peptic ulcer, atrial fibrillation, triple-vessel disease, and left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), in addition to key medications (antiplatelet drugs, statins, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [ACEI/ARB], and beta-blockers). Post-exposure interventions (procedural anticoagulation, access site) and laboratory indicators affected by acute phase interference were excluded to avoid overadjustment bias, and the subgroup analyses were conducted to explore differential effects. Potential nonlinear relationships between the AM-LDL index and clinical outcomes (bleeding events, MACE, NACE) were assessed using restricted cubic spline (RCS) analyses with the rms package in R (version 4.3.0). Knots were placed at clinically relevant percentiles (5%, 50%, 95%) of AM-LDL distribution, as recommended for biomedical applications. Knot positions were confirmed via the Akaike Information Criterion (AIC)-based optimization (range tested: 3–5 knots). The 50th percentile served as the reference point, corresponding to a Hazard Ratio (HR) of (1) The covariates adjusted in RCS analysis were identical to those incorporated in Multivariable Cox proportional hazards regression Model (2) Statistical significance was defined as a two-sided P-value < 0.05 for all analyses. Sample size calculation The PASS 15.0 software was employed for sample size calculation. In light of the fact that this was a retrospective cohort study, the power analysis was conducted based on the event rates across groups for a multiple sample rates test. Adequate statistical power (> 0.8) was achieved for the highest quartile relative to the lowest, thereby supporting the reliability of this result. Result Baseline characteristics Among the 5658 participants, 309 experienced BARC ≥ 2 bleeding, 156 had MACE, and 454 developed NACE. AM-LDL quartiles were used to stratify the patients into four groups, using threshold values of 122.12 mmol/L·year, 160.25 mmol/L·year, and 200.96 mmol/L·year. Baseline characteristics are presented in Table 1, with statistically significant disparities observed among the groups. Patients in higher AM-LDL groups were typically older and more often female, and they also showed a higher burden of hypertension, whereas the prevalence of CAD and diabetes was lower. Additionally, they more frequently received statin therapy and continuous DAPT. Table 1Baseline characteristics, grouped by baseline AM-LDLAM-LDL (mmol/L·years)Q1(< 122.12)(n = 1414)Q2(122.12–160.25)(n = 1415)Q3(160.25–200.96)(n = 1413)Q4(≥ 200.96)(n = 1416) P Sociodemographics Age, median (IQR)57.00 (49.00,65.00)60.00 (52.00,68.00)63.00 (56.00,71.00)67.00 (61.00,74.00)0.000 Gender (Female), n (%)207 (14.6)257 (18.2)286 (20.2)481 (34.0)0.000 BMI, median (IQR)25.00 (23.21,27.70)24.86 (23.00,27.00)24.80 (2.90,26.70)24.60 (22.80,26.60)0.000 Smoking, n (%)788 (55.8)726 (51.5)694 (49.1)582 (41.2)0.000 Drinking, n (%)334(23.6)268(18.9)233(16.5)212(25.0)0.000Comorbidities, n (%) Coronary heart disease527 (37.3)402 (28.5)313 (22.2)294 (20.8)0.000 Heart failure50 (3.6)58 (4.1)47 (3.3)59 (4.2)0.567 Hypertension835 (59.1)805 (56.9)841 (59.5)882 (62.3)0.034 Diabetes483 (34.2)393 (27.8)418 (29.6)374 (26.5)0.000 Chronic renal insufficiency51 (3.6)44 (3.1)36 (2.5)35 (2.5)0.238 Cerebral vascular disease153 (10.8)151 (10.7)150 (10.6)155 (11.0)0.990 Peptic ulcer50 (3.5)38 (2.7)55 (3.9)38 (2.7)0.162 Atrial fibrillation47(3.3)28(2.0)45(3.2)48(3.4)0.088 prior PCI261 (19.9)178 (13.8)132 (10.3)115 (9.0)0.000Diagnosis, n (%) STEMI529 (37.4)609 (43.0)703 (49.8)689 (48.7)0.000 NSTEMI346 (24.5)394 (27.8)379 (26.8)341 (24.1)0.062 UA539 (38.1)410 (29.0)331 (23.4)386 (27.3)0.000Physical examination median, (IQR) Heart rate72.00 (65.00,80.00)74.00 (67.00,83.00)74.00 (66.00,83.00)75.00 (66.00,85.00)0.001 Systolic blood pressure128.00 (115.00,140.00)128.00 (115.00,141.00)130.00 (115.00,144.00)132.00 (118.00,147.00)0.000Laboratory examination, (IQR) LVEF, (%)59.00 (52.00,64.00)58.00 (52.00,63.00)58.00 (50.00,63.00)58.00 (51.00,63.00)0.015 Hemoglobin, (g/L)140.00 (128.00,150.00)140.00 (128.00,151.00)140.00 (129.00,152.00)139.00 (126.25,150.00)0.067 Hematocrit, (L/L)0.41 (0.38,0.44)0.41 (0.38,0.44)0.41 (0.38,0.45)0.41 (0.38,0.44)0.186 White blood cell count, (10^9/L)7.44 (5.97,9.51)8.03 (6.33,10.33)8.30 (6.53,10.79)8.12 (6.60,10.41)0.000 Platelet count, (10^9/L)207.00 (171.00,252.25)210.00 (176.00,254.00)213.00 (175.00,252.00)215.00 (180.00,256.00)0.000 eGFR, (mL/min/1.73 m²)95.09 (80.25,112.74)95.41 (78.98,113.20)93.32 (76.39,111.24)90.01 (73.35,106.43)0.000 eGFR < 60 mL/min/1.73 m², n (%)92 (6.6)106 (7.6)124 (8.9)152 (10.9)0.000Interventional procedure, n (%) Left main disease94(6.6)105(7.4)102(7.2)126(8.9)0.133 Triple-vessel disease493(34.9)520(36.7)575(40.7)617(43.6)0.000 Multi-vessel disease847(60.0)877(62.0)877(62.1)916(64.7)0.074 Primary PCI324(22.9)476(33.6)572(40.5)583(41.2)0.000 Femoral artery access88(6.2)104(7.3)123(8.7)119(8.4)0.059Postoperative anticoagulant therapy, n (%) GPIIb/IIIa receptor antagonists300(21.2)300(21.2)347(24.6)334(23.6)0.082 Low molecular weight heparin332(23.5)377(26.6)362(25.6)351(24.8)0.258 Bivalirudin9(0.6)10(0.7)8(0.6)7(0.5)0.898Post discharge antiplatelet therapy, n (%)0.033 Continuous use of Clopidogrel + Aspirin805 (56.9)812 (57.4)763 (54.0)784 (55.4) Continuous use of Ticagrelor + Aspirin333 (23.6)311 (22.0)313 (22.2)354 (25.0) Non-continuous DAPT276 (19.5)292 (20.6)337 (23.8)278 (19.6)Combination therapy, n (%) Statin1095 (77.4)1142 (80.7)1138 (80.5)1212 (85.6)0.000 Proton pump inhibitor725 (51.3)708 (50.0)729 (51.6)784 (55.4)0.029 Beta-blocker1186 (83.9)1209 (85.4)1208 (85.5)1234 (87.1)0.106 Calcium channel blocker944 (66.8)1012 (71.5)1015 (71.8)1083 (76.5)0.000 ACEI/ARB803 (56.8)821 (58.0)870 (61.6)854 (60.3)0.042Abbreviations: All abbreviations used in this table are defined in the Methods section or as per common clinical usage; Q1-Q4, quartiles 1 to 4 Table 1Baseline characteristics, grouped by baseline AM-LDLAM-LDL (mmol/L·years)Q1(< 122.12)(n = 1414)Q2(122.12–160.25)(n = 1415)Q3(160.25–200.96)(n = 1413)Q4(≥ 200.96)(n = 1416) P Sociodemographics Age, median (IQR)57.00 (49.00,65.00)60.00 (52.00,68.00)63.00 (56.00,71.00)67.00 (61.00,74.00)0.000 Gender (Female), n (%)207 (14.6)257 (18.2)286 (20.2)481 (34.0)0.000 BMI, median (IQR)25.00 (23.21,27.70)24.86 (23.00,27.00)24.80 (2.90,26.70)24.60 (22.80,26.60)0.000 Smoking, n (%)788 (55.8)726 (51.5)694 (49.1)582 (41.2)0.000 Drinking, n (%)334(23.6)268(18.9)233(16.5)212(25.0)0.000Comorbidities, n (%) Coronary heart disease527 (37.3)402 (28.5)313 (22.2)294 (20.8)0.000 Heart failure50 (3.6)58 (4.1)47 (3.3)59 (4.2)0.567 Hypertension835 (59.1)805 (56.9)841 (59.5)882 (62.3)0.034 Diabetes483 (34.2)393 (27.8)418 (29.6)374 (26.5)0.000 Chronic renal insufficiency51 (3.6)44 (3.1)36 (2.5)35 (2.5)0.238 Cerebral vascular disease153 (10.8)151 (10.7)150 (10.6)155 (11.0)0.990 Peptic ulcer50 (3.5)38 (2.7)55 (3.9)38 (2.7)0.162 Atrial fibrillation47(3.3)28(2.0)45(3.2)48(3.4)0.088 prior PCI261 (19.9)178 (13.8)132 (10.3)115 (9.0)0.000Diagnosis, n (%) STEMI529 (37.4)609 (43.0)703 (49.8)689 (48.7)0.000 NSTEMI346 (24.5)394 (27.8)379 (26.8)341 (24.1)0.062 UA539 (38.1)410 (29.0)331 (23.4)386 (27.3)0.000Physical examination median, (IQR) Heart rate72.00 (65.00,80.00)74.00 (67.00,83.00)74.00 (66.00,83.00)75.00 (66.00,85.00)0.001 Systolic blood pressure128.00 (115.00,140.00)128.00 (115.00,141.00)130.00 (115.00,144.00)132.00 (118.00,147.00)0.000Laboratory examination, (IQR) LVEF, (%)59.00 (52.00,64.00)58.00 (52.00,63.00)58.00 (50.00,63.00)58.00 (51.00,63.00)0.015 Hemoglobin, (g/L)140.00 (128.00,150.00)140.00 (128.00,151.00)140.00 (129.00,152.00)139.00 (126.25,150.00)0.067 Hematocrit, (L/L)0.41 (0.38,0.44)0.41 (0.38,0.44)0.41 (0.38,0.45)0.41 (0.38,0.44)0.186 White blood cell count, (10^9/L)7.44 (5.97,9.51)8.03 (6.33,10.33)8.30 (6.53,10.79)8.12 (6.60,10.41)0.000 Platelet count, (10^9/L)207.00 (171.00,252.25)210.00 (176.00,254.00)213.00 (175.00,252.00)215.00 (180.00,256.00)0.000 eGFR, (mL/min/1.73 m²)95.09 (80.25,112.74)95.41 (78.98,113.20)93.32 (76.39,111.24)90.01 (73.35,106.43)0.000 eGFR < 60 mL/min/1.73 m², n (%)92 (6.6)106 (7.6)124 (8.9)152 (10.9)0.000Interventional procedure, n (%) Left main disease94(6.6)105(7.4)102(7.2)126(8.9)0.133 Triple-vessel disease493(34.9)520(36.7)575(40.7)617(43.6)0.000 Multi-vessel disease847(60.0)877(62.0)877(62.1)916(64.7)0.074 Primary PCI324(22.9)476(33.6)572(40.5)583(41.2)0.000 Femoral artery access88(6.2)104(7.3)123(8.7)119(8.4)0.059Postoperative anticoagulant therapy, n (%) GPIIb/IIIa receptor antagonists300(21.2)300(21.2)347(24.6)334(23.6)0.082 Low molecular weight heparin332(23.5)377(26.6)362(25.6)351(24.8)0.258 Bivalirudin9(0.6)10(0.7)8(0.6)7(0.5)0.898Post discharge antiplatelet therapy, n (%)0.033 Continuous use of Clopidogrel + Aspirin805 (56.9)812 (57.4)763 (54.0)784 (55.4) Continuous use of Ticagrelor + Aspirin333 (23.6)311 (22.0)313 (22.2)354 (25.0) Non-continuous DAPT276 (19.5)292 (20.6)337 (23.8)278 (19.6)Combination therapy, n (%) Statin1095 (77.4)1142 (80.7)1138 (80.5)1212 (85.6)0.000 Proton pump inhibitor725 (51.3)708 (50.0)729 (51.6)784 (55.4)0.029 Beta-blocker1186 (83.9)1209 (85.4)1208 (85.5)1234 (87.1)0.106 Calcium channel blocker944 (66.8)1012 (71.5)1015 (71.8)1083 (76.5)0.000 ACEI/ARB803 (56.8)821 (58.0)870 (61.6)854 (60.3)0.042Abbreviations: All abbreviations used in this table are defined in the Methods section or as per common clinical usage; Q1-Q4, quartiles 1 to 4 Baseline characteristics, grouped by baseline AM-LDL Abbreviations: All abbreviations used in this table are defined in the Methods section or as per common clinical usage; Q1-Q4, quartiles 1 to 4 Clinical stratification and temporal trends The stratification analysis based on the quartiles of AM-LDL revealed a significant gradient change in clinical characteristics and outcomes with the elevation of AM-LDL levels. In terms of LDL-C target achievement rate, 58.8% of patients in the quartile 1 (Q1) group (AM-LDL < 122.12 mmol/L·year) met the guideline-recommended target (LDL-C < 1.8 mmol/L), whereas the rate plummeted to 6.4% in the quartile 2 (Q2) group (AM-LDL between 122.12 and 160.25 mmol/L·year). Notably, none of the patients in the quartile 3 (Q3) (AM-LDL between 160.25 and 200.96 mmol/L·year) and quartile 4 (Q4) groups (AM-LDL ≥ 200.96 mmol/L·year) achieved the target, with both groups exhibiting a rate of 0%. The intergroup differences reached statistical significance (χ² = 2525.504, P < 0.001) (Fig. 2). Further analysis indicated that for each quartile increase in AM-LDL, the target achievement rate decreased by an average of 19.6% points (χ² = 14.223, P < 0.001). Regarding clinical outcomes, the 1-year follow-up data showed a progressive increase in the incidence of MACE from 1.6% in the Q1 group to 4.0% in the Q4 group (trend test χ² = 14.223, P = 0.002). The incidence of NACE followed a comparable trend, which rose from 6.2% in the Q1 group to 9.5% in the Q4 group (trend test χ² = 13.783, P = 0.002). However, it is worth noting that no significant intergroup differences were found in the rates of clinically relevant (BARC ≥ 2) bleeding (χ² = 7.359, P = 0.061) (Table 2; Fig. 2). Table 2Clinical outcomes stratified by AM-LDL indexAM-LDL (mmol/L·years)Q1(< 122.12)(n = 1414)Q2(122.12–160.25)(n = 1415)Q3(160.25–200.96)(n = 1413)Q4(≥ 200.96)(n = 1416) P BARC ≥ 2 bleeding, n (%)66 (4.7)68 (4.8)95 (6.7)80 (5.6)0.061MACE, n (%)23 (1.6)36 (2.5)41 (2.9)56 (4.0)0.002NACE, n (%)88 (6.2)100 (7.1)132 (9.3)134 (9.5)0.002 Table 2Clinical outcomes stratified by AM-LDL indexAM-LDL (mmol/L·years)Q1(< 122.12)(n = 1414)Q2(122.12–160.25)(n = 1415)Q3(160.25–200.96)(n = 1413)Q4(≥ 200.96)(n = 1416) P BARC ≥ 2 bleeding, n (%)66 (4.7)68 (4.8)95 (6.7)80 (5.6)0.061MACE, n (%)23 (1.6)36 (2.5)41 (2.9)56 (4.0)0.002NACE, n (%)88 (6.2)100 (7.1)132 (9.3)134 (9.5)0.002 Clinical outcomes stratified by AM-LDL index Fig. 2Incidence rate of BARC ≥ 2 bleeding, MACE, NACE and the achievement of LDL-C targets as a function of AM-LDL quartiles. The ESC guideline goal (LDL-C < 1.8 mmol/L) is marked by the dashed line. Bar data presented as mean ± SD Incidence rate of BARC ≥ 2 bleeding, MACE, NACE and the achievement of LDL-C targets as a function of AM-LDL quartiles. The ESC guideline goal (LDL-C < 1.8 mmol/L) is marked by the dashed line. Bar data presented as mean ± SD Association of AM-LDL with bleeding event, MACE, and NACE Based on Kaplan-Meier estimates, the AM-LDL level was positively correlated with the cumulative incidence of MACE and NACE (log-rank P = 0.002 for both endpoints), while no significant correlation was observed with bleeding risk (P = 0.055). Furthermore, the cumulative incidence of MACE and NACE increased progressively with higher AM-LDL (Fig. 3). A multivariable Cox model was employed, with adjustments for age, sex, BMI, smoking, drinking history, medical histories of CAD, hypertension, diabetes, peptic ulcer and atrial fibrillation, and eGFR, LVEF, triple-vessel disease, as well as the use of antiplatelet therapy, statin, beta-blocker and ACEI/ARB. Patients with AM-LDL between 160.25 and 200.96 mmol/L·year (Q3) had a significantly elevated risk of BARC ≥ 2 bleeding (HR = 1.457, 95%CI:1.005–2.112, P = 0.0427) and NACE (HR = 1.540, 95%CI: 1.112–2.133, P = 0.009) compared to those in the lowest exposure group (Q1). Patients with AM-LDL greater than 200.96 mmol/L·year (Q4) exhibited a significant increase in risk for MACE (HR = 2.623, 95%CI: 1.411–4.876, P = 0.002) and NACE (HR = 1.520, 95%CI: 1.094–2.111, P = 0.012) (Table 3). In addition, component-specific analyses were conducted in the prospectively adjudicated BRIC II subcohort (n = 3861). As shown in Supplementary Table 1, only all-cause mortality demonstrated statistically significant differences across AM-LDL quartiles, with the highest quartile exhibiting persistently elevated MACE risk after multivariable adjustment (HR = 2.191, 95% CI:1.049–4.574, P = 0.037), which is consistent with the results of the full cohort. For bleeding event rate, while statistical significance was attenuated in the full cohort analysis (P = 0.061) compared to BRIC II (P = 0.023), the fundamental monotonic risk gradient remained consistent (Supplementary Table 2, Supplementary Fig. 1). Fig. 3Kaplan–Meier curves of BARC ≥ 2 bleeding (A), MACE (B), and NACE (C) by the quartile of AM-LDL after a 1-year follow-up in total ACS patients. Clinically meaningful separations between AM-LDL quartiles are highlighted in panels B and C through magnified insets (lower-right quadrant) Kaplan–Meier curves of BARC ≥ 2 bleeding (A), MACE (B), and NACE (C) by the quartile of AM-LDL after a 1-year follow-up in total ACS patients. Clinically meaningful separations between AM-LDL quartiles are highlighted in panels B and C through magnified insets (lower-right quadrant) Table 3Association between AM-LDL and BARC ≥ 2 Bleeding, MACE and NACE analyzed by Cox hazard regression modelevent rate(%)UnadjustedModel 1Model 2HR(95CI%) P HR(95CI%) P HR(95CI%) P BARC ≥ 2 BleedingContinuous scale5.51.001 (1.000,1.003)0.1121.001 (0.999,1.003)0.3411.001 (0.999,1.003)0.419 Q14.7RefRefRef Q24.81.066 (0.758,1.499)0.7121.046 (0.742,1.474)0.7991.194 (0.809,1.763)0.372 Q36.71.484 (1.082,2.035)0.0141.458 (1.061,2.004)0.0201.457 (1.005,2.112)0.047 Q45.61.254 (0.904,1.741)0.1761.188 (0.852,1.657)0.3101.203 (0.815,1.775)0.353P for trend0.0570.0730.254MACEContinuous scale2.81.005 (1.002,1.007)0.0001.004 (1.002,1.007)0.0001.004 (1.001,1.007)0.006 Q11.6RefRefRef Q22.51.573 (0.932,2.655)0.0901.553(0.911,2.647)0.1061.899 (0.991,3.642)0.053 Q32.91.798 (1.079,2.995)0.0241.758 (1.044,2.959)0.0341.887 (0.984,3.620)0.056 Q44.02.454 (1510,3.987)0.0002.339 (1.424,3.845)0.0012.623 (1.411,4.876)0.002P for trend0.0030.0080.025NACEContinuous scale8.01.003 (1.001,1.004)0.0001.002 (1.001,1.004)0.0021.002 (1.000,1.003)0.039 Q16.2RefRefRef Q27.11.147 (0.861,1.528)0.3481.137 (0.851,1.518)0.3851.343 (0.961,1.877)0.084 Q39.31.528 (1.167,2.001)0.0021.495 (1.139,1.964)0.0041.540 (1.112,2.133)0.009 Q49.51.543 (1.180,2.020)0.0021.427 (1.083,1.881)0.0121.520 (1.094,2.111)0.012P for trend0.0020.0110.043Model 1 adjusts for gender, BMI, smoking, and drinkingModel 2 adjusts for the history of coronary heart disease, hypertension, diabetes, peptic ulcer, atrial fibrillation, eGFR, LVEF, triple-vessel disease, post discharge antiplatelet therapy (the classification criteria are consistent with Table 1), statin, beta-blockers, ACEI/ARB based on Model 1. Table 3Association between AM-LDL and BARC ≥ 2 Bleeding, MACE and NACE analyzed by Cox hazard regression modelevent rate(%)UnadjustedModel 1Model 2HR(95CI%) P HR(95CI%) P HR(95CI%) P BARC ≥ 2 BleedingContinuous scale5.51.001 (1.000,1.003)0.1121.001 (0.999,1.003)0.3411.001 (0.999,1.003)0.419 Q14.7RefRefRef Q24.81.066 (0.758,1.499)0.7121.046 (0.742,1.474)0.7991.194 (0.809,1.763)0.372 Q36.71.484 (1.082,2.035)0.0141.458 (1.061,2.004)0.0201.457 (1.005,2.112)0.047 Q45.61.254 (0.904,1.741)0.1761.188 (0.852,1.657)0.3101.203 (0.815,1.775)0.353P for trend0.0570.0730.254MACEContinuous scale2.81.005 (1.002,1.007)0.0001.004 (1.002,1.007)0.0001.004 (1.001,1.007)0.006 Q11.6RefRefRef Q22.51.573 (0.932,2.655)0.0901.553(0.911,2.647)0.1061.899 (0.991,3.642)0.053 Q32.91.798 (1.079,2.995)0.0241.758 (1.044,2.959)0.0341.887 (0.984,3.620)0.056 Q44.02.454 (1510,3.987)0.0002.339 (1.424,3.845)0.0012.623 (1.411,4.876)0.002P for trend0.0030.0080.025NACEContinuous scale8.01.003 (1.001,1.004)0.0001.002 (1.001,1.004)0.0021.002 (1.000,1.003)0.039 Q16.2RefRefRef Q27.11.147 (0.861,1.528)0.3481.137 (0.851,1.518)0.3851.343 (0.961,1.877)0.084 Q39.31.528 (1.167,2.001)0.0021.495 (1.139,1.964)0.0041.540 (1.112,2.133)0.009 Q49.51.543 (1.180,2.020)0.0021.427 (1.083,1.881)0.0121.520 (1.094,2.111)0.012P for trend0.0020.0110.043Model 1 adjusts for gender, BMI, smoking, and drinkingModel 2 adjusts for the history of coronary heart disease, hypertension, diabetes, peptic ulcer, atrial fibrillation, eGFR, LVEF, triple-vessel disease, post discharge antiplatelet therapy (the classification criteria are consistent with Table 1), statin, beta-blockers, ACEI/ARB based on Model 1. Association between AM-LDL and BARC ≥ 2 Bleeding, MACE and NACE analyzed by Cox hazard regression model Model 1 adjusts for gender, BMI, smoking, and drinking Model 2 adjusts for the history of coronary heart disease, hypertension, diabetes, peptic ulcer, atrial fibrillation, eGFR, LVEF, triple-vessel disease, post discharge antiplatelet therapy (the classification criteria are consistent with Table 1), statin, beta-blockers, ACEI/ARB based on Model 1. Nonlinear dose-response relationship between AM-LDL with bleeding event, MACE, and NACE The RCS analysis indicated no significant association between AM-LDL and BARC ≥ 2 bleeding after adjusting for relevant risk factors (P-overall > 0.05). In contrast, a linear positive correlation was observed between AM-LDL and MACE (P-nonlinear > 0.05) (Fig. 4). Critically, dose-response analysis indicated a nonmonotonic, inverted U-shaped relationship of the AM-LDL index with NACE risk (P-overall = 0.021; P-nonlinear = 0.038), with an inflection point at AM-LDL = 302.609 mmol/L·years. When AM-LDL < 302.609 mmol/L·years, NACE risk showed a nonsignificant increasing trend (HR = 0.001, 95%CI: 0.705–1.418). Conversely, when AM-LDL > 302.609 mmol/L·years, NACE risk showed a nonsignificant decreasing trend (HR = 0.999, 95%CI: 0.703–1.421). Fig. 4Multivariable adjusted HR for BARC ≥ 2 bleeding (A), MACE (B), and NACE (C) across a continuous range of AM-LDL levels. The solid red lines represent the adjusted HRs, with shaded bands indicating the 95% CI derived from restricted cubic spline regression (3 knots). The dashed black line (HR = 1.0) denotes the reference for no association. The covariates adjusted in RCS analysis were identical to those incorporated in Multivariable Cox proportional hazards regression Model 2 Multivariable adjusted HR for BARC ≥ 2 bleeding (A), MACE (B), and NACE (C) across a continuous range of AM-LDL levels. The solid red lines represent the adjusted HRs, with shaded bands indicating the 95% CI derived from restricted cubic spline regression (3 knots). The dashed black line (HR = 1.0) denotes the reference for no association. The covariates adjusted in RCS analysis were identical to those incorporated in Multivariable Cox proportional hazards regression Model 2 Sensitivity analysis AM-LDL served as a superior predictor for MACE and NACE in specific subgroups—namely males, non-smokers, patients without atrial fibrillation, and those with preserved renal function (eGFR ≥ 60 mL/min/1.73 m²), as presented in Supplementary Tables 3 and illustrated in Supplementary Fig. 2. Similarly, it is better only for MACE in CAD combined, LVEF < 50%, and non-primary PCI patients. When stratified by whether the baseline LD-LC levels met the guideline-recommended standard of ≤ 1.8 mmol/L, the AM-LDL was more likely to predict the future risk of MACE in ACS patients who did not meet the target levels. No significant effect modification by advanced age (≥ 65 years) was observed on the associations of AM-LDL with bleeding, MACE, or NACE risks. DAPT comprising aspirin and clopidogrel showed a trend toward a reduced risk of BARC ≥ 2 bleeding, although the statistical significance is not pronounced. Conversely, it exerted a significant adverse effect on the incidence of MACE. The impact of continuous aspirin combined with ticagrelor and intermittent DAPT on bleeding, MACE, and NACE does not exhibit statistical significance. In exploratory analyses, AM-LDL demonstrated unadjusted positive correlations with Framingham 10-year risk score [13] (Pearson’s r = 0.22, P < 0.001), though this association requires confirmation in adjusted models (Supplementary Fig. 3). Discussion The Age-Multiplied LDL-C index, calculated from routine admission data, demonstrates differentiated risk profiles for adverse outcomes in ACS-PCI patients. It exhibits a robust linear association with 1-year ischemic events (MACE), independent of traditional risk factors, while showing no significant link to bleeding risk. Notably, a nonlinear inverted U-shaped relationship with NACE was observed (inflection point ≈ 300 mmol/L·years), though trends beyond this point lacked statistical significance. These findings position AM-LDL as a potential tool for personalized risk stratification, highlighting candidates who may optimally benefit from early lipid-lowering intensification focused on ischemia mitigation without hemorrhagic trade-offs. However, the exploratory nature of the NACE relationshipand the retrospective, single-center design necessitate caution. To corroborate these findings and precisely define the AM-LDL inflection point, subsequent large-scale prospective investigations are needed to firmly establish its role in guiding personalized treatment intensification. Findings from Mendelian randomization and clinical studies indicate that LDL-C influences atherosclerotic cardiovascular disease (ASCVD) risk as a function of both present level and cumulative lifetime burden. A comprehensive review that appeared in the Journal of the American College of Cardiology (JACC) in 2018 first proposed that cumulative LDL-C exposure (LDL-C level multiplied by age) may represent a useful metric for estimating lifetime plaque burden, suggesting that patients are at minimal risk of heart attack during the asymptomatic plaque progression phase when their cumulative LDL-C exposure is below a threshold. However, once this threshold is exceeded, the risk of myocardial infarction increases over time, and a minimum cumulative LDL-C exposure threshold of 5000 mg·years was estimated by the study [8]. This study extends this concept to ACS secondary prevention, demonstrating that the AM-LDL index (age × admission LDL-C) captures synergistic effects of current dyslipidemia and vascular aging. This reveals critical limitations of conventional LDL targets (e.g., LDL-C < 1.8 mmol/L): 0% of patients in the highest AM-LDL quartile (Q4) achieved targets, with a 2.6-fold higher MACE risk vs. Q1. These findings align with mechanisms of vascular aging—downregulated cholesterol efflux (e.g., ABCA1) and reduced nitric oxide (NO) bioavailability exacerbate LDL toxicity [14]. The current research mainly focuses on the absolute level of LDL-C, but it is clear that the management strategy based on a single LDL threshold in the current guidelines exposes significant deficiencies under the stratification of AM-LDL. Especially for the Chinese population, patients with AM-LDL > 160.25 mmol/L·year could not reach the standard (0%) even after receiving statin treatment, suggesting that relying solely on the absolute value of LDL may underestimate the treatment needs of high-risk groups. Notably, the weak correlation between AM-LDL and Framingham risk scores (ρ = 0.24) highlights AM-LDL’s unique capacity to quantify “age-LDL synergy,” a dimension overlooked by traditional models. These findings support the integration of AM-LDL into risk stratification to optimize therapeutic decisions. Specifically, patients with AM-LDL ≥ 200 mmol/L·year might be considered for early PCSK9 inhibitor initiation, pending prospective validation. While some literature has linked low LDL-C levels to hemorrhagic stroke and major in-hospital bleeding [10, 15], and high cholesterol levels to a protective effect against bleeding [16–18], the underlying mechanisms of cholesterol-related bleeding remain obscure. It is speculated that lipids may play a role in preserving cell membrane integrity and fluidity [19, 20]. In this study, the positive association between AM-LDL levels and BARC ≥ 2 bleeding risk showed a lack of statistical significance, which could be explained by the multiple factors affecting bleeding events, including the age-related platelet hyperreactivity counterbalancing LDL-lowering effects and high P2Y12 inhibitor usage masking lipid-related bleeding tendencies [21]. This dissociation ensures that AM-LDL-guided intensification can prioritize ischemic risk without hemorrhagic trade-offs. Notably, an inverted U-shaped relationship between AM-LDL and NACE was identified by restricted cubic spline analysis (P-nonlinear = 0.038), with an inflection point observed at approximately 300 mmol/L·years. This paradoxical pattern—where NACE risk peaked at moderate AM-LDL levels but trended downward at higher exposures—contrasts with the linear association observed for ischemic events. Several potential explanations are proposed: first, the composite nature of NACE (encompassing both ischemia and bleeding) may reflect competing risks; second, in response to very high AM-LDL levels, clinicians might intuitively intensify LLT in an effort to mitigate the patient’s net risk; third, biological thresholds in vascular aging could exist where excessive LDL burden triggers compensatory mechanisms. Importantly, trends beyond the inflection point lacked statistical significance (HR ≈ 1.0), urging caution against overinterpretation. This exploratory finding underscores the complexity of net risk prediction and highlights the need for future studies to validate the inflection threshold and disentangle its drivers through larger cohorts with detailed treatment-adjustment data. The NATURE-PARADOX study presented at the 2023 ESC Congress further emphasized the relationship linking cumulative LDL-C exposure to ASCVD absolute risk, suggesting its potential as a unique biomarker for assessing plaque burden and tracking plaque progression [9]. These studies concentrate on the risk of CAD in patients without atherosclerosis, which underscores the critical role of cumulative LDL-C exposure for primary prevention strategies. By extending the “cumulative exposure” concept to ACS secondary prevention, this study bridges a critical knowledge gap. Unlike the NATURE-PARADOX trial, which focused on plaque progression, AM-LDL demonstrates acute-phase prognostic utility for 1-year ischemic events. Its clinical appeal lies in rapid calculability (age × admission LDL), enabling real-time risk assessment during early ACS management. For exploratory purposes, it is proposed that a risk-stratified approach be considered: AM-LDL ≥ 200 mmol/L·year consider PCSK9i at discharge; AM-LDL 160–199 mmol/L·year intensify statin/ezetimibe; AM-LDL < 160 mmol/L·year maintain standard therapy. These thresholds require validation in interventional trials. Notably, the compressed 1-year observation window inherently limits absolute event rates in this study. Annualizing longer-term registry data contextualizes this finding: Converting EPICOR Asia’s 2-year MACE rate (6.2%) yields 3.1%/year, while ODYSSEY’s 2.8-year rate (7.72%) equates to 2.76%/year—nearly identical to this 1-year MACE rate in this study (2.76%) [22, 23]. Similarly, the event rate in this study (5.46%) aligns with contemporary Chinese real-world evidence (e.g., Ma et al.) [24], collectively reflecting modern ACS management efficacy. Importantly, cohort differences further explain rate variations: the present population included 30% unstable angina cases versus ~ 20% in ODYSSEY OUTCOMES, implying lower baseline ischemic risk. In addition, the observed prevalence of moderate renal dysfunction in this present cohort (8.38% with eGFR < 60 mL/min/1.73 m²) is lower than in Qi et al.‘s study (21%) and China PEACE study (18.1%) [25, 26], a difference attributable to fundamental cohort distinctions. First, this present population was younger (mean age 61.7 years vs. 65.6 in Qi et al. and 63.4 in China PEACE) with markedly different ACS phenotypes: about 30% unstable angina and 44.7% STEMI versus 53% and 58% STEMI in Qi et al. and China PEACE. This profile is consequential—UA patients typically present with less myocardial necrosis and inflammatory stress, mitigating acute renal injury risk. Second, STEMI-dominant cohorts inherently carry higher renal risk due to contrast-induced nephropathy exposure and catecholamine surge. Moreover, the subgroup analysis revealed an important nuance regarding renal function. While the association between AM-LDL index and outcomes remained consistent in patients with preserved renal function (eGFR ≥ 60 mL/min/1.73 m²), no statistically significant associations were observed in those with reduced eGFR (< 60 mL/min/1.73 m²). This divergence may be attributed to several interrelated factors. First, advanced renal dysfunction fundamentally alters cardiovascular risk pathways—including uremia-induced endothelial toxicity, aberrant lipid metabolism, and calcification patterning—which may dominate over or mask the atherogenic momentum captured by AM-LDL [27]. Second, the reduced sample size in this subgroup (n = 474, 8.38% of cohort) limited statistical power. Future studies with targeted CKD enrollment are warranted to validate or refine this index in renal impairment populations. Strengths and limitations This study is characterized by several major strengths. It is derived from the large-scale, prospective, multicenter BRIC study, providing strong statistical power and generalizability. The use of standardized electronic case report forms facilitated the acquisition of high-quality, consistent clinical data. All patients completed one-year follow-up under a structured protocol, minimizing loss to follow-up and supporting reliable outcome assessment. Furthermore, an independent Clinical Events Committee was tasked with adjudicating all endpoint events based on pre-specified standard criteria to guarantee classification objectivity and accuracy. These elements collectively enhance the validity and clinical applicability of these findings. Several limitations inherent to the study’s design and context should be considered. First, as a post hoc analysis of observational registry data, it cannot establish causality, and unmeasured confounders (e.g., genetic factors, dietary habits) may persist despite multivariable adjustment. Second, data collection constraints introduced specific gaps: (1) Oral anticoagulant (OAC) use was not systematically captured; however, contemporary Chinese ACS registries demonstrate exceptionally low OAC utilization (CCC-ACS: 1.6% AF prevalence with 0.22% OAC usage rate) [10]. The low and balanced AF rate (3.0%) in this cohort, combined with statistical adjustment and subgroup analysis, makes substantial confounding by OAC unlikely. (2) Detailed malignancy history was unavailable; while malignancy prevalence in STEMI populations is low (≈ 2.2%) [28], future studies should explicitly screen for cancer, particularly to define lipid thresholds during immunosuppressive therapy. (3) Longitudinal LDL-C data were lacking due to the protocol-mandated, limiting precise cumulative burden quantification; future work should employ sophisticated exposure modeling (e.g., LDL-year calculators). (4) Adherence to DAPT was assessed via interviews/records rather than quantitative measures (e.g., medication possession ratios), potentially overestimating compliance due to self-reporting bias, although this reflects real-world registry constraints. Third, during the study period (2014–2019), lipid management in China relied predominantly on moderate-intensity statins, with PCSK9 inhibitors inaccessible and ezetimibe used as predominantly second-line. While the AM-LDL index demonstrates prognostic value within this statin-focused context, granular statin intensity data were not captured in source records, precluding dose-stratified analysis, and the index’s performance remains untested with contemporary lipid-lowering regimens. Consequently, validation in cohorts receiving high-intensity statins or novel agents (e.g., PCSK9 inhibitors) is essential to establish broader applicability. Fourth, the MACE composite excluded heart failure hospitalizations (HHF) and unstable angina due to diagnostic complexities and potential dilution of associations with objective ischemic outcomes. While this aligns with standardized ACS trials, for example EPICOR Asia trial and ODYSSEY trial [22, 23], it precludes assessment of AM-LDL’s association with these events. The authors’ prospective registry (NCT06738758) is addressing this gap through protocolized HHF/UA adjudication. Finally, the 1-year follow-up precludes long-term risk assessment, and absent protocol-mandated lipid testing limited LDL-C attainment analysis. Collectively, these underscore the need for validation in diverse populations with higher OAC/malignancy burdens, longer follow-ups with serial lipid monitoring, and interventional studies establishing causality. Conclusion In Chinese ACS-PCI patients, the Age-Multiplied LDL-C (AM-LDL) index—calculated from universally available admission parameters—demonstrates a linear association with 1-year ischemic events, an inverted U-shaped relationship with net adverse clinical events, and no significant link to BARC ≥ 2 bleeding events. This profile positions AM-LDL as a promising risk-stratification tool to guide the early intensification of LLT by pinpointing ACS patients at elevated ischemic risk. And also, the dissociation of the AM-LDL index from bleeding risk suggests that such therapeutic intensification can be prioritized without the expectation of increased hemorrhagic complications, thereby helping to optimize the benefit-risk ratio of secondary prevention, providing a practical strategy to alleviate the burden of cardiovascular diseases. Its key clinical relevance lies in its potential to refine risk stratification at discharge—a critical juncture for therapeutic planning. Future research should prioritize investigating whether AM-LDL-guided therapy can improve clinical outcomes compared to standard care, particularly through validation in large-scale, prospective clinical trials. To address this objective, the authors have initiated the “Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients (ELITE-ACS)” trial (NCT06738758). This study aims to integrate real-world lipid monitoring data to establish evidence-based benchmarks for personalized lipid management in ACS, which is crucial for optimizing strategies for cardiovascular disease prevention and management. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4.